💊Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

By JPN, Pharmaceutical

💊Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases .

Deal combines HemoShear’s REVEAL-Tx™ platform with Takeda’s drug discovery and development capabilities.
October 17, 2017 Osaka, Japan and Charlottesville, Va.

Takeda Pharmaceutical Company Limited (TSE: 4502) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).

https://www.takeda.com/newsroom/newsreleases/2017/hemoshear2/

More from tokioX :

  1. Opioid Crackdown Could Lead To More Drug Company Bankruptcies
  2. 🔬Nikon | News | Nikon Corporation and Yumanity Therapeutics Enter Contract for the Commission Development of Drug Discovery Assay System in Neurodegenerative Diseases
  3. 💊Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases
  4. 💊Drug Discovery Today
  5. 💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo
  6. 🔬National Center for Health and Medicine and Dai Nippon Printing started joint research towards drug discovery support using the next generation organ chip “mini gut”
  7. アステラス、ギルテリチニブが急性骨髄性白血病（AML）治療薬としてFDAよりオーファンドラッグ（希少疾病用医薬品）の指定